{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:04:34Z","timestamp":1773151474807,"version":"3.50.1"},"reference-count":43,"publisher":"Informa UK Limited","issue":"10","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2023,10,3]]},"DOI":"10.1080\/14737175.2023.2246658","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T13:27:13Z","timestamp":1691846833000},"page":"853-858","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapy"],"prefix":"10.1080","volume":"23","author":[{"given":"Eszter","family":"Czifrus","sequence":"first","affiliation":[{"name":"Semmelweis University Faculty of Medicine, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Berlau","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Regis University School of Pharmacy, Denver, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,8,12]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3"},{"key":"e_1_3_4_4_1","unstructured":"Duchenne muscular dystrophy - about the disease - genetic and rare diseases information center. [cited 2023 Mar 31]. https:\/\/rarediseases.info.nih.gov\/diseases\/6291\/duchenne-muscular-dystrophy"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ANA.23528"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/S13018-022-02996-8"},{"key":"e_1_3_4_8_1","unstructured":"Duchenne muscular dystrophy - symptoms causes treatment | NORD. [cited 2023 Mar 29]. https:\/\/rarediseases.org\/rare-diseases\/duchenne-muscular-dystrophy\/#symptoms"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2015.03.008"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/JMEDGENET-2015-103387"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/JNNP.2007.141721"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-005-2584-x"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10654-020-00613-8"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30025-5"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30026-7"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70271-6"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107719"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32160-8"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210682"},{"key":"e_1_3_4_21_1","unstructured":"A Treatment Option For Amenable Patients | EXONDYS 51 (eteplirsen) injection. [cited 2023 Apr 4. https:\/\/www.exondys51hcp.com\/amenability"},{"key":"e_1_3_4_22_1","volume-title":"Exondys 51 [Prescribing information]","year":"2016","unstructured":"Exondys 51 [Prescribing information]. Cambridge, MA: Sarepta Therapeutics, Inc.; 2016."},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/MUS.20586"},{"key":"e_1_3_4_24_1","volume-title":"Amondys 45 [Prescribing information]","year":"2021","unstructured":"Amondys 45 [Prescribing information]. Cambridge, MA: Sarepta Therapeutics, Inc.; 2021."},{"key":"e_1_3_4_25_1","volume-title":"Vyondys 53 [Prescribing information]","year":"2019","unstructured":"Vyondys 53 [Prescribing information]. Cambridge, MA: Sarepta Therapeutics, Inc.; 2019."},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/NAT.2020.0845"},{"key":"e_1_3_4_27_1","volume-title":"Viltepso [Prescribing information]","year":"2020","unstructured":"Viltepso [Prescribing information]. Paramus, NJ: NS Pharma, Inc.; 2020."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S288842"},{"key":"e_1_3_4_29_1","unstructured":"Viltolarsen: drug information - UpToDate. [cited 2023 Mar 29]. https:\/\/www.uptodate.com\/contents\/viltolarsen-drug-information?search=viltolarsen&source=panel_search_result&selectedTitle=1~5&usage_type=panel&kp_tab=drug_general&display_rank=1#F54802954"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000417"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210696"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0713"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51235"},{"key":"e_1_3_4_34_1","unstructured":"Longitudinal study of the natural history of Duchenne muscular dystrophy (DMD) - full text view - ClinicalTrials.Gov. [cited 2023 May 8]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00468832"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1264"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-220811"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221656"},{"key":"e_1_3_4_38_1","unstructured":"Study to assess the efficacy and safety of viltolarsen in ambulant boys with DMD (RACER53) - full text view - ClinicalTrials.Gov. [cited 2023 Mar 29]. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04060199"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000418"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01339-3"},{"key":"e_1_3_4_41_1","unstructured":"FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation | FDA. [cited 2023 Mar 29]. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation"},{"key":"e_1_3_4_42_1","unstructured":"Medicines Agency E. Public summary of opinion on orphan designation viltolarsen for the treatment of Duchenne muscular dystrophy. Published online 2020. [cited 2023 Mar 29]. www.ema.europa.eu\/contact"},{"key":"e_1_3_4_43_1","unstructured":"Pharma NS. NS Pharma Reports on Results of VILTEPSO\u00ae (viltolarsen) injection After Four Years of Treatment in Open-Label Extension Trial in Duchenne Muscular Dystrophy [Press release]. [cited 2022 Oct 24]. https:\/\/www.nspharma.com\/pdfs\/WMS_Data_Press_Release_final.pdf"},{"key":"e_1_3_4_44_1","unstructured":"Vyondys 53. [cited 2023 May 8]. https:\/\/www.vyondys53.com\/#getstarted"},{"key":"e_1_3_4_45_1","unstructured":"University of Alberta: New treatment could benefit up to 45% of patients with Duchenne \u2013 Defeat Duchenne Canada. [cited 2023 May 8]. https:\/\/defeatduchenne.ca\/university-of-alberta-new-treatment-could-benefit-up-to-45-of-patients-with-duchenne\/"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2023.2246658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T18:50:36Z","timestamp":1695149436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2023.2246658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,12]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,3]]}},"alternative-id":["10.1080\/14737175.2023.2246658"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2023.2246658","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}